Understanding the Respiratory Delivery of High Dose Anti-Tubercular Drugs

Shyamal C. Das, Peter J. Stewart

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

4 Citations (Scopus)


This chapter considers the respiratory delivery of drugs used in the treatment of tuberculosis (TB), an infectious disease caused by the bacterium Mycobacterium tuberculosis. It provides a rationale for respiratory delivery of anti-tubercular drugs to the lungs, including the targeting of alveolar macrophages and granulomas. The doses of anti-tubercular drugs are high and most formulations will be carrier free containing drug and limited amounts of excipient. The aerosolization of high dose drugs existing in a cohesive matrix will be related to de-agglomeration processes. The chapter outlines the studies that have occurred in this area using particle engineering approaches. Formulations of particles or engineered particles which possess a suitable size for respiratory delivery can be considered as cohesive matrices. The particles in the matrix will interact due to the various interactive forces that exist between particles, including contact potential forces, Coulombic forces, intermolecular forces, capillary force and solid bridging.

Original languageEnglish
Title of host publicationDrug Delivery Systems for Tuberculosis Prevention and Treatment
EditorsAnthony J. Hickey, Amit Misra, P. Bernard Fourie
Place of PublicationChichester West Sussex UK
PublisherJohn Wiley & Sons
Number of pages17
ISBN (Electronic)9781118943182
ISBN (Print)9781118943175
Publication statusPublished - 26 Aug 2016

Publication series

NameAdvances in Pharmaceutical Technology
PublisherJohn Wiley & Sons, Ltd


  • Anti-tubercular drugs
  • Carrier free containing drug
  • Cohesive matrix
  • De-agglomeration processes
  • Mycobacterium tuberculosis
  • Particle engineering approaches
  • Respiratory delivery

Cite this